Sign in
Taking people in United StatesNo phase

Stent grafts for aneurysms of the main body artery in the chest and belly

Tests stent grafts for complex aortic aneurysms in people at high risk for open surgery.

Key facts

Who runs it
Darren Schneider, M.D.
Where
New York and Philadelphia, United StatesSee the 2 sites
Trial code
Registry title
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Status
Recruiting
People taking part
520 people, planned
Started
Nov 2013
Expected to end
Dec 2033
Type of study
Interventional, 2 groups
Treatments tested
  • Endovascular treatment of Thoracoabdominal Aortic Aneurysm
  • Endovascular treatment of Aortic Arch Aneurysms
Record updated
15 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a large thoracoabdominal aortic aneurysm (a bulge in the main artery of the chest and belly) or an aortic arch aneurysm. They must be at high risk for open surgery. They are treated with a stent graft placed through the arteries.

Age
18 years and older.
Sex
Men and women.
Disease stage
TAAA: at least 6 cm (2.4 in) in men or 5 cm in women. It can also be larger than 5 cm (2 in) (men) or 4.5 cm (1.8 in) (women) and growing more than 10mm/year. Or a TAAA with an iliac artery aneurysm of at least 4 cm (1.6 in). Arch aneurysm: same size limits, or a saccular (pouch-shaped) arch aneurysm that doctors see as at significant risk of bursting. Arteries must have a shape and size that allow the device to be placed. Life expectancy must be more than 2 years.
Earlier treatment
High risk for open surgery is shown by things like age (≥ 65 year for TAAA, > 70 years for arch), prior aortic surgery, heart, lung or kidney disease. For the arch arm, prior ascending or arch repair, ≥2 sternotomies (chest-opening surgeries) or prior neck radiation also count.

Main reasons for not taking part

  • Burst aneurysm with low blood pressure (systolic bp < 90), or acute aortic dissection.
  • Pregnancy or breastfeeding.
  • Serious body-wide or groin infection, infected (mycotic) aneurysm, or bleeding disorder that cannot be corrected.
  • Known Marfan or Ehler-Danlos Syndrome, or allergy to device materials such as nitinol, stainless steel or gold.
  • People able and willing to be treated with a device already on the market or in a manufacturer-sponsored pivotal study.

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Presence of TAAA in:; Men with TAAA greater than or equal to 6 cm in diameter; Women with TAAA greater than or equal to 5 cm in diameter; Men with TAAA larger than 5 cm in diameter and enlarging at a rate of more than 10mm/year; Women with TAAA larger than 4.5 cm in diameter and enlarging at a rate of more than 10mm/year or; Men or women with TAAA and an iliac artery aneurysm greater than or equal to 4 cm in diameter
  • Life expectancy more than 2 years
  • Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol
  • Suitable arterial anatomy for endovascular TAAA repair with "TAAA device":; Proximal aortic landing zone:; ≥ 20mm long; ≤ 40mm and ≥ 20mm diameter in parallel aorta; free from circumferential thrombus; ≤ 60 degrees angulation; Mesenteric/renal aortic diameter ≥ 20mm; Mesenteric arteries:; ≥ 10mm long segment of healthy artery for branch attachment; Diameter ≥ 4mm and ≤ 12mm; Absence of aberrant or early branching, aneurysm or dissection; Renal arteries:; ≥ 10mm long segment of healthy artery for branch attachment; Diameter ≥ 4mm and ≤ 8mm; Absence of aberrant or early branching, aneurysm or dissection; Iliac artery access:; ≥ 6mm diameter, and absence of severe calcification and tortuosity; Or, planned creation of surgical conduit for TAAA device delivery; For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use):; ≥ 10mm long segment of healthy internal iliac artery for branch attachment; Internal iliac diameter ≥ 5mm and ≤ 12mm; External iliac diameter ≥ 6mm diameter, and absence of severe calcification and tortuosity; Minimum common iliac artery luminal diameter ≥ 14mm; Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery
  • Patients deemed high risk for open repair (meeting one, or more, of the following criteria):; Age ≥ 65 year; Cardiac disease:; CAD (history of MI or angina with positive stress test and not revascularizable); LV Ejection fraction < 40%; Symptomatic CHF (NYHC Class II, III, or IV); Pulmonary disease:; Home oxygen therapy; FEV1 < 1.2 l/s; Vital capacity < 50% predicted; PaCO2 > 45 mm Hg or < 60 mm Hg; Renal disease:; ESRD on dialysis; eGFR < 60; Prior aortic surgery; Hostile abdomen; Portal hypertension (ascites or varices); Coagulopathy; AORTIC ARCH STUDY ARM
  • Presence of aortic arch aneurysm in:; Men with aortic arch aneurysm greater than or equal to 6 cm in diameter, or; Women with aortic arch aneurysm greater than or equal to 5 cm in diameter, or; Men with aortic arch aneurysm larger than 5 cm in diameter and enlarging at a rate of more than 10 mm/year, or; Women with aortic arch aneurysm larger than 4.5 cm in diameter and enlarging at a rate of more than 10 mm/year, or; Saccular aortic arch aneurysms deemed at significant risk for rupture based upon physician interpretation
  • Life expectancy more than 2 years
  • Ability to give informed consent, complete pre-treatment assessments and comply with the follow-up schedule per protocol
  • Suitable arterial anatomy for endovascular aortic arch repair with "Aortic Arch Device":; Aneurysm of the aortic arch beginning distal to the native coronary arteries or any patent coronary artery bypass; Proximal aortic landing zone:; Native aorta or surgical graft; ≥ 20 mm long; ≤ 42 mm and ≥ 20 mm diameter in parallel aorta; free from circumferential thrombus; Distal aortic landing zone:; Native aorta or surgical graft; ≥ 20 mm long; ≤ 42 mm and ≥ 20 mm diameter in parallel aorta; free from circumferential thrombus; ≥ 50mm length from native coronary arteries or patent coronary bypass graft to innominate artery; Adequate supra-aortic trunk branch landing zone(s):; Innominate artery (if applicable):; Native vessel or surgical graft; Diameter: 8-22mm; Length of sealing zone ≥10mm; Acceptable tortuosity; Absence of dissection in landing zone; Left (or right) common carotid artery (if applicable):; Native vessel or surgical graft; Diameter 6-16mm; Length of sealing zone ≥10mm; Acceptable tortuosity; Absence of dissection in landing zone; Left (or right) subclavian artery (if applicable):; Native vessel or surgical graft; Diameter: 5-20mm; Length of sealing zone ≥10mm; Acceptable tortuosity; Absence of dissection in landing zone; Iliac artery access:; ≥ 6mm diameter, and absence of severe calcification and tortuosity; Or, planned creation of surgical conduit for TAAA device delivery
  • Patients deemed high risk for open surgical aortic arch repair based upon consensus of both a qualified cardiac surgeon and a qualified vascular surgeon and meeting one, or more, of the following criteria):; Age > 70 years-old; Prior ascending or aortic arch repair; Multiple (≥2) median sternotomies; Ischemic cardiomyopathy with multi-level coronary artery disease and/or positive stress test; Chronic pulmonary disease with FEV1 < 1500ml; Chronic kidney disease with eGFR ≤ 60 ml/kg/hr; Large aneurysm abutting the sternotomy; Severe deconditioning or immobility; Prior cervical irradiation; Other medical condition associated with prohibitive high risk with open repair based upon multidisciplinary consensus (cardiac surgery and vascular surgery); APPLIES TO BOTH STUDY ARMS

Who cannot take part

  • Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome (unless proximal implantation is into a previously placed surgical graft)
  • Participation in another in another investigational device or drug study within 1 year of treatment
  • Unrelated concomitant major surgical or interventional procedure(s) within 30 days of treatment date (with the exception of staged procedures planned as part of treatment)
  • Patients able and willing to be treated with a commercially available device or a device being evaluated in a manufacturer-sponsored pivotal study
  • Serious systemic or groin infection
  • Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold
  • Age < 18 years
  • Rupture, with hypotension (systolic bp < 90)
  • Pregnancy or breastfeeding
  • Unwillingness or inability to comply with the follow up schedule
  • Uncorrectable coagulopathy
  • Mycotic aneurysm
  • Body habitus that would inhibit X-ray visualization of the aorta
  • Acute aortic dissection

Other criteria

  • TAAA STUDY ARM

Where in United States

  • New York - Presbyterian HospitalNew York, United StatesContact: Darren Schneider, MDNo longer taking part
  • Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Darren Schneider, MDTaking people

About the trial

What the trial wants to find out

Prospective, nonrandomized, single-center, two-arm study to assess the feasibility and safety and to evaluate clinical outcomes of endovascular repair of complex aortic aneurysms (thoracoabdominal aortic aneurysms and aortic arch aneurysms) in patients at high risk for open surgery.

The 2 groups in the trial

  • TAAA (thoracoabdominal aortic aneurysm) Study ArmTreatment being tested

    Either the Off-the-Shelf TAAA device or the Physician-Specified TAAA Device will be implanted. The Off-the-Shelf TAAA Device is a standard configuration Zenith t-Branch with four branches for the mesenteric arteries and the renal arteries. The Physician-Specified TAAA Devices may include a combination of up to 5 fenestrations and branches for mesenteric and renal arteries. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards.

    Treatment: Endovascular treatment of Thoracoabdominal Aortic Aneurysm

  • Aortic Arch Study ArmTreatment being tested

    Physician-specified aortic arch stent graft device with up to 3 antegrade and/or retrograde branches or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery\] to treat aortic aneurysms involving the aortic arch in patients at high risk for open surgery.

    Treatment: Endovascular treatment of Aortic Arch Aneurysms

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility, Safety, and Clinical Outcomes of Endovascular Treatment of Thoracoabdominal Aortic Aneurysms and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Plain-language title
Stent grafts for aneurysms of the main body artery in the chest and bellyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
15 December 2025